Health News Archive - May 19, 2011
BARCELONA, May 19, 2011 /PRNewswire/ -- Iroko Cardio International (Geneva, Switzerland), a privately held pharmaceutical company dedicated to reducing the incidence of major adverse cardiac events (MACE), has adopted Veeva CRM to support all of its representatives in nine European countries. Both field and office-based users have begun to leverage the advanced functionality of the new system to manage their customer information and interactions, citing quick deployment, ease of use, cost efficiency, and scalability as key benefits thus far. "I've lived through several CRM implementations before, and the 'sell' to end users was never easy," confided Juergen Guenther, vice president of customer operations at Iroko.
AMSTERDAM, May 19, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive.
MELVILLE, N.Y., May 19, 2011 /PRNewswire/ -- Nycomed US Inc., a wholly owned subsidiary of Nycomed, announced today that it will become an independent corporation and will no longer be affiliated with Nycomed following the acquisition of its parent company by Takeda Pharmaceutical Company Ltd.
OSAKA, Japan, and ZURICH, May 19, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Nycomed A/S ("Nycomed") jointly announced today that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for 9.6 billion Euro on a cash-free, debt-free basis.
MONHEIM, Germany, May 19, 2011 /PRNewswire/ -- - Online Campaign Fronted by Garfield Launches to Educate the Owners of Middle Aged Cats About Chronic Kidney Disease A new campaign launched today will educate cat owners about the risk of chronic kidney disease (CKD) that their pets may face as they grow older and urge them to seek kidney function tests for cats over the age of seven.
BRADFORD, England, May 19, 2011 /PRNewswire/ -- Predator Nutrition is preparing to inject the BodyPower Expo 2011 with a powerful boost of energy after being named the official distributor for Omega Sports. As Europe's leading distributor of sports nutrition products and bodybuilding supplements, Predator Nutrition will be at the very heart of this weekend's gathering of the great and good of the health, fitness and nutrition industry.
SHANGHAI, May 19, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its financial results for its first quarter ended March 31, 2011. To help management and investors gain a better understanding of ShangPharma's operating performance, the Company presents certain non-GAAP measures, each of which excludes expenses relating to or the effect of share-based compensation.
BOSTON, May 19, 2011 /PRNewswire/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced results of a global survey conducted during its webinar entitled "Critical Tasks of Site Monitors: Using a CTMS to Improve Efficiency." Perceptive polled biopharmaceutical industry professionals across a broad range of clinical, data management and IT functions about the value of providing Clinical Research Associates (CRAs) with access to a Clinical Trial Management System (CTMS) to assist in site monitoring and management activities during clinical trials. The survey results revealed that 89% of respondents provide CRAs with access to either a CTMS or other monitoring tool.
AUSTIN, Texas, May 19, 2011 /PRNewswire/ -- There is good news for the 76 million Americans who experience chronic pain including migraine, back pain, fibromyalgia and arthritis.
CARLSBAD, Calif., May 19, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a Phase 1 clinical study for ISIS-TTRRx.